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An essential prerequisite of nonangiogenic growth appears to be the ability of the tumour to preserve the parenchymal structures of
the host tissue. This morphological feature is visible on a routine tissue section. Based on this feature, we classified haematoxylin and
eosin-stained tissue sections from 279 patients with non-small-cell lung cancer into three growth patterns: destructive (angiogenic;
n¼196), papillary (intermediate; n¼38) and alveolar (nonangiogenic; n¼45). A Cox multiple regression model was used to test
the prognostic value of growth patterns together with other relevant clinicopathological factors. For overall survival, growth
pattern (P¼0.007), N-status (P¼0.001), age (P¼0.020) and type of operation (P¼0.056) were independent prognostic factors.
For disease-free survival, only growth pattern (P¼0.007) and N-status (Po0.001) had an independent prognostic value. Alveolar
(hazard ratio¼1.825, 95% confidence interval¼1.117–2.980, P¼0.016) and papillary (hazard ratio¼1.977, 95% confidence
interval¼1.169–3.345, P¼0.011) growth patterns were independent predictors of poor prognosis. The proposed classification has
an independent prognostic value for overall survival as well as for disease-free survival, providing a possible explanation for survival
differences of patients in the same disease stage.
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Although a large number of papers have been published evaluating
prognostic factors in cancer (Cannistra, 2000), TNM-staging is still
the most important tool used to estimate prognosis for lung cancer
patients and to select the best possible combination of treatment
modalities. Although TNM-staging gives an accurate estimate of the
progression of the disease at the time of diagnosis, it does not always
account for survival differences. Resected stage I non-small-cell lung
cancer (NSCLC) is a typical example with wide differences in
survival for tumours resected at an identical early stage.
The last few decades have been characterised by a move in
cancer research from a reductionistic approach focusing mainly on
the cancer cell itself to a greater appreciation of the importance of
interactions between cancer cells and stroma. This has resulted in
much new information concerning molecular–biological processes
that take place in the stroma, one of which is the formation of new
blood vessels, angiogenesis.
In the past 10 years, more than 100 papers have been published
studying various components of angiogenesis and their relation to
prognosis in lung carcinoma, but results so far are inconclusive or
awaiting confirmation and clinical practice has not been altered
(Cox et al, 2000; Shepherd and Sridhar, 2003; Yano et al, 2003).
The hypothesis that tumour growth is dependent on angio-
genesis (Folkman, 1990), which prevailed for many years, has been
challenged with the description of nonangiogenic growth. In a
study of 500 NSCLC, an ‘alveolar’ growth pattern was described, in
which the tumour cell nests filled the alveolar spaces without
destruction of lung parenchyma, co-opting the septal blood vessels
(Pezzella et al, 1997). A subsequent study confirmed this growth
pattern to be nonangiogenic (Passalidou et al, 2002). Nonangio-
genic growth patterns have also been described in liver
(Vermeulen et al, 2001; Stessels et al, 2004), lymph node
(Vermeulen et al, 2002b) and lung metastases (Pezzella, 2000).
An essential prerequisite for nonangiogenic growth appears to
be the ability of the tumour to preserve the stromal architecture
of the host tissue. With the advent of antiangiogenic drugs, the
vasculo-morphological growth pattern may have a clinical value
as it could be used as a surrogate marker of angiogenesis.
Additionally, these growth patterns may have prognostic impor-
tance. The prognostic value of the alveolar, nonangiogenic growth
pattern has been suggested in four studies (Pastorino et al, 1997;
Pezzella et al, 1997; Offersen et al, 2001; Funai et al, 2003). The aim
of this study was to test the prognostic value of growth patterns
using a modification of the classification of NSCLC into growth
patterns previously proposed by Pezzella et al (1997).
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Study population
All relevant clinical information was gathered retrospectively from
369 consecutive patients who underwent curative surgical resec-
tion for primary NSCLC at the University Hospital of Antwerp
between January 1991 and January 2001. Standardised forms were
completed based on the in-patient medical records and the medical
records of the consultant respiratory physician in our department
or in the referral hospital. All patients were operated on by the
same surgeon (PVS). The pathological TNM-staging of NSCLC was
used based on histopathology reports and on the perioperative
findings (Mountain, 1997). The disease-free interval was defined as
disease-free survival time or the interval between surgery and
relapse. Relapse was defined as local recurrence, metastasis or
both. Recurrence was confirmed on both clinical, radiological and/
or biopsy results. A total of 90 patients were excluded from further
analyses: 26 (7.0%) due to perioperative mortality (two died during
the operation and 24 within 30 days or during the same
hospitalisation), 26 who had received induction chemotherapy,
11 patients with metastases observed at the time of surgery, six
patients with a double tumour at the time of diagnosis, five
patients who underwent a double surgical procedure (coronary
bypass and lobectomy), three patients who had had metastasect-
omy for a solitary brain metastasis prior to lung operation and 13
due to poor quality tissue sections or tissue sections without
recognisable interface between tumour and normal lung tissue. A
total of 279 patients (241 men and 38 women) were included in the
study.
Morphological analysis
Haematoxylin and eosin (H&E)-stained tissue sections from all
tumour blocks from each patient were examined. Tumours were
classified according to growth patterns based on two considera-
tions: firstly, preservation or destruction of lung parenchyma at
the lung–tumour interface and, secondly, presence or absence of a
tumour-associated stroma at the lung–tumour interface (Figure 1).
The interface was defined as a field of  100 magnification at the
edge of the tumour, containing only tumour tissue, next to normal
lung tissue. Based on these criteria, tumours were classified into
three growth patterns as follows:
(1) Destructive growth pattern (angiogenic growth pattern):
destruction of lung parenchyma with the presence of
tumour-associated stroma at the interface.
(2) Papillary growth pattern (intermediate growth pattern):
preservation of the alveolar structure of the lung parenchyma
at the interface with formation of stromal stalks containing
capillary vessels originating from the alveolar septa, suggest-
ing co-option of alveolar blood vessels with subsequent
angiogenesis.
(3) Alveolar growth pattern (nonangiogenic): preservation of the
alveolar structure of lung parenchyma with co-option of septal
blood vessels and without evidence of new stroma formation
at the interface. In this growth pattern, solid tumour cell nests
fill the alveolar spaces, often with the presence of necrosis in
the centre of these nests. This group does not include
bronchiolo-alveolar carcinoma (BAC), which is characterised
by orderly replacement of pneumocytes by tumour cells along
the alveolar septa without infiltration, necrosis or fibrovas-
cular proliferation. The studied patient population contained
only three BACs according to WHO classification. However,
the patients presenting these tumours had different nodules in
different lung lobes at the time of diagnosis. So these patients
were excluded, because they had M1 status at the time of
operation.
The growth patterns described are characteristics of the whole
tumour tissue at the interface. For a tumour to be classified as
alveolar or papillary, this tumour growth had to be present
throughout the whole interface. In very few cases, a mixed growth
pattern was observed at the interface. In these few cases, a major
destructive component was always observed with a minor alveolar
or papillary component. So, these tumours were included in the
destructive group.
The growth patterns described are morphological features
different from the histiotypes and are based on biological
behaviour of the tumour tissue with respect to the lung
parenchyma; alveolar growth pattern must not be confused with
bronchiolo-alveolar histological subtype of adenocarcinomas.
The proposed classification is based upon the study of Pezzella
et al as shown in Table 1. The following modifications were
made: (1) the ‘diffuse’ and ‘basal’ categories were merged into
the ‘destructive’ group; (2) growth patterns were based only on
the properties of the interface; (3) classification was made using
Non-small-cell lung cancer 
 Preservation of 
lung parenchyma 
Destruction of
lung parenchyma
Without
stroma formation  Stroma formation  Stroma formation 
 Alveolar 
nonangiogenic 
 (co-option) 
Papillary 
intermediate 
(co-option and angiogenesis) 
Destructive 
angiogenic 
(angiogenesis) 
Figure 1 Classification of non-small-cell lung cancer.
Table 1 Modified classification of NSCLC based on growth patterns
Growth pattern Determination
Vascularisation at
interface
Destruction of lung
parenchyma at
interface
Formation of stroma
at interface
Corresponding growth
pattern according to
Pezzella et al (1997)
Destructive (angiogenic) At the interface Only newly formed vessels Destruction Present Diffuse and basal
Papillary (intermediate) At the interface Newly formed vessels
admixed with pre-existing
vessels
No destruction Present Papillary
Alveolar (nonangiogenic) At the interface Pre-existing vessels No destruction Absent Alveolar (entirely
alveolar)+partially alveolar
(basal, diffuse)
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stained for vascular markers.
Statistical analysis
Survival effects were evaluated using Kaplan–Meier plots, and the
differences were assessed by the log-rank test. In order to assess
the presence of confounding, the distribution of known prognostic
factors between growth patterns was analysed by the w
2 test for
categorical variables. Continuous variables, age and size of the
tumour were tested for normality with the Kolmogorov–Smirnov
test. The distribution of these factors between growth patterns was
assessed by the Kruskal–Wallis test, because these factors were not
normally distributed.
Potential confounders were entered into a Cox multiple
regression model for overall survival as well as for disease-free
survival. The model building was guided by the influence of the
inclusion of these factors on the regression coefficient. The
disease-free survival analysis was performed for 267 patients
because in 12 cases the disease-free survival time could not be
exactly determined. The estimates were presented with a 95%
confidence interval or with standard error. The analyses were
performed with SPSS for Windows (Release 11.5 SPSS Inc.).
RESULTS
The median patient age at the time of the operation was 66 years
(range: 39–87). According to postoperative TNM-staging, 77
(27.6%) patients were in stage IA, 90 (32.3%) patients in stage
IB, 12 (4.3%) patients in stage IIA, 60 (21.5%) patients in stage IIB,
17 (6.1%) patients in stage IIIA and 23 (8.2%) patients were in
stage IIIB. A total of 52 (18.6%) patients received postoperative
radiotherapy. The median follow-up of the whole group was 34
months (range: 2–135). Kaplan–Meier survival estimate at 5 years
for the whole group was 54.7% (standard error (s.e.)¼3.5%) and
estimates for stage IA and IB were 66.4% (s.e.¼6.4%) and 63.3%
(s.e.¼5.9%), respectively.
At the moment of final evaluation for this study (January 2003),
163 (58.4%) patients were alive of whom 137 (49.1%) were disease
free, 119 (42.7%) had relapsed, 16 (5.7%) had developed a second
primary and 116 (41.6%) had died (Table 2). In total, 31% of the
patients with a relapse had developed local recurrence, 67% had
developed metastases and 2% had developed both.
Based upon our classification, 196 (70.3%) patients had a
tumour with a destructive growth pattern (Figure 2A), 38 (13.4%)
patients had a tumour with a papillary growth pattern (Figure 2B)
and 45 (16.1%) patients had a tumour with an alveolar growth
pattern (Figure 2C).
The Kaplan–Meier survival analyses of different clinicopatho-
logical factors for overall survival and disease-free survival are
presented in Table 3. Factors that were significant for overall
survival and disease-free survival were the type of operation, the
T-status, the N-status, the stage of the disease, postoperative
Table 2 Status at the end of follow-up
Alive Dead Total
Recurrence 25 94 119
Second primary 10
a 6
a 16
a
Dead of other causes — 13
a 13
a
Not known 1 3 4
Disease free 137 19 156
Total 163 116 279
aPatients with a second primary and dead of other causes were considered disease
free.
Figure 2 Growth patterns of non-small cell lung cancer are visible on
routine H&E-stained tissue sections. (A) Destructive growth pattern
(angiogenic): parenchymal structures of the lung are not preserved, but
replaced by carcinoma cells and tumour-associated stroma. (B) Papillary
growth pattern (intermediate): the lung parenchyma is preserved with
formation of fibrovascular stalks originating from the alveolar septa. (C)
Alveolar growth pattern (nonangiogenic): the tumour cell nests fill the
alveolar spaces with preservation of alveolar septa and without formation
of a tumour-associated stroma.
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at 5 years for destructive, papillary and alveolar growth pattern
were 60.7% (s.e.¼4.0%), 38.9% (s.e.¼9.6%) and 43.0%
(s.e.¼10%), respectively. Kaplan–Meier survival curves for
disease-free survival of patients in stage l according to growth
pattern are shown in Figure 3.
The association of different clinicopathological findings with
growth patterns is presented in Table 4. There were no significant
differences in distribution of clinicopathological factors between
different growth patterns, except for histiotype and size of the
tumour. The papillary growth pattern was exclusively seen in
adenocarcinomas (in 100%) and tumours with this growth pattern
tended to be smaller.
Cox multiple regression analyses
Based on the results obtained by Kaplan–Meier survival analyses
and descriptive analyses, the following factors were entered into
Cox multiple regression analyses: age (as continuous variable),
gender (male or female), type of operation ((bi)lobectomy or
pneumonectomy), histiotype (adenocarcinoma, squamous cell
carcinoma, large-cell carcinoma or others), postoperative radio-
therapy or not, localisation (left or right lung), N-status (N0, N1 or
N2), T-status (T1, T2, T3 or T4), growth pattern (destructive,
papillary or alveolar) and the interaction variable (growth
pattern histiotype). This interaction variable was included
because a strong association was found between histiotype and
growth pattern in descriptive analyses (Table 4).
For overall survival, alveolar growth pattern, papillary growth
pattern, advanced N-status, higher age and pneumonectomy were
independent predictors of poor prognosis (Table 5). The interac-
tion variable was not significant (P¼0.574).
For disease-free survival, alveolar growth pattern, papillary
growth pattern and advanced N-status were independent pre-
dictors of local recurrence and/or metastasis (Table 6). The
interaction variable was not significant (P¼0.427).
Table 3 Univariate analysis of different clinicopathological factors for overall survival (OS) and disease-free survival (DFS)
OS (months) DFS (months)
n Median (s.e.
b) 95% CI
a P-value Median (s.e.) 95% CI P-value
Gender
Male 241 77 (13) 51–103 Nr —
female 38 Nr
c — 0.2677 84 (37) 12–156 0.8626
Histiotype
Adenocarcinoma 93 59 (10) 40–78 Nr —
Squamous 128 87 (11) 66–108 0.6150 Nr — 0.4168
Large cell 42 Nr — 0.8902 Nr — 0.8088
other 16 Nr — 0.7518 71 (44) 0–156 0.9604
Localisation
Left 122 69 (12) 46–92 84 (30) 26–124
right 157 90 (11) 65–111 0.1260 Nr — 0.1295
Type of operation
(Bi)lobectomy 192 94 (12) 70–118 Nr —
Pneumonectomy 87 35 (7) 21–49 0.0004 22 (6) 10–34 0.0005
T-status
T1 89 94 (15) 64–124 102 (17) 68–136
T2 147 72 (15) 44–100 0.1050 Nr — 0.0646
T3 20 Nr — 0.8880 Nr — 0.2792
T4 23 37 (9) 19–55 0.0151 18 (2) 15–21 0.0011
N-status
N0 198 102 (10) 83–121 Nr —
N1 64 39 (8) 23–55 0.0002 27 (12) 3–51 0.0009
N2 17 29 (8) 13–45 0.0001 12 (3) 5–19 o0.0001
Stage
St IA 77 94 (15) 65–123 Nr —
St IB 90 90 (10) 70–110 0.6234 Nr — 0.3330
St IIA 12 46 (2) 41–51 0.0623 22 (21) 0–63 0.0135
St IIB 60 58 (24) 12–104 0.0098 71 (28) 17–125 0.0055
St IIIA 17 29 (7) 14–44 0.0001 12 (7) 0–25 o0.0001
St IIIB 23 37 (9) 19–55 0.0045 18 (2) 15–21 0.0001
Radiotherapy
No 227 90 (11) 68–112 Nr —
received 52 33 (10) 14–52 0.0074 21 (4) 14–28 0.0003
Growth pattern
Destructive 196 96 (13) 71–121 Nr —
Papillary 38 48 (10) 28–68 0.1640 Nr — 0.3039
Alveolar 45 59 (25) 10–108 0.0130 22 (11) 0–44 0.0070
a95% CI¼95% confidence interval.
bs.e.¼standard error.
cNot reached.
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For clinical relevance, a subanalysis was performed for patients in
stage IA and IB and the following factors were entered into Cox
multiple regression analyses: age (as continuous variable), gender
(male or female), type of operation ((bi)lobectomy or pneumo-
nectomy), histiotype (adenocarcinoma, squamous cell carcinoma,
large-cell carcinoma or others), localisation (left or right lung), T-
status (T1 or T2), growth pattern (destructive, papillary or
alveolar) and the interaction variable (growth pat-
tern histiotype).
For overall survival, alveolar growth pattern, papillary growth
pattern and higher age were independent predictors of poor
prognosis (Table 7). The interaction variable was not significant
(P¼0.689).
For disease-free survival, alveolar and papillary growth pattern
were the only independent predictors of local recurrence and/or
metastasis (Table 8). The interaction variable was not significant
(P¼0.412).
DISCUSSION
We have found that growth pattern is an independent prognostic
factor in patients with NSCLC. Interestingly, growth pattern is one
of the most important independent prognostic factors in stage I
NSCLC, giving a possible explanation for survival differences
among patients with stage I disease. The clinical relevance of this
finding is important since patients at risk for early relapse and
early mortality can be recognised based on a reproducible
characteristic of the tumour tissue, the growth pattern, visible on
a routine H&E-stained tissue section.
The classification of NSCLC into growth patterns was first
proposed by Pezzella et al (1997). Based upon frequency tables,
they observed that the patients with a purely alveolar growth
pattern (alveolar growth throughout the whole tumour section)
had a higher recurrence rate than other patients. In a companion
paper, 515 patients with pathological stage I NSCLC were analysed.
The tumours were classified in purely alveolar growth pattern
(n¼80, 16%) and angiogenic growth pattern (the remainder). The
prognostic importance of the alveolar growth pattern was assessed.
In the whole group, purely alveolar growth pattern did not have a
prognostic value, but when the analyses were performed for the
137 patients classified as pT1N0, purely alveolar growth pattern
(n¼21) was associated with a poorer outcome (Pastorino et al,
1997). A subsequent study of the phenotypical characteristics of
endothelial cells indicated that the alveolar growth pattern is
nonangiogenic as the incorporated blood vessels do not express
the integrin aVb3, a putative marker of endothelial cells
participating in angiogenesis, and stain positively for LH39,
expressed on mature basement membrane (Passalidou et al, 2002).
Our proposed classification is a modification of the classifica-
tion by Pezzella et al and is based on the properties of the
tumour–lung interface only. We believe that this is the region
where the tumour expands and where the tumour–stroma
interaction is most active. The highest mean microvessel density
(MVD) and the highest VEGF/KDR (vascular endothelial growth
Growth pattern and stage I
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Figure 3 Disease-free survival according to growth pattern for patients
in stage I (destructive vs papillary growth, P¼0.0455 and destructive vs
alveolar growth pattern, P¼0.0465).
Table 4 Association of different clinicopathological factors with growth
patterns
Items
Destructive
N (%)
Papillary
N (%)
Alveolar
N (%) P-value
Number of cases 196 (70.3) 38 (13.4) 45 (16.1)
Gender 0.069
Female 21 (10.7) 9 (23.7) 8 (17.8)
Male 175 (89.3) 29 (76.3) 37 (82.2)
Age
a (years) 65 (40–87) 65 (42–77) 66 (39–80) 0.324
Histiotype o0.0001
Adenocarcinoma 43 (21.9) 38 (100) 12 (26.7)
Squamous cell 110 (56.1) — 18 (40.0)
Large cell 29 (14.8) — 13 (28.9)
others 14 (7.1) — 2 (4.4)
Localisation 0.264
Left lung 89 (45.4) 12 (31.6) 21 (46.7)
Right lung 107 (54.6) 26 (68.4) 24 (53.3)
Stage 0.245
IA 47 (24.0) 16 (42.1) 14 (31.1)
IB 60 (30.6) 13 (34.2) 17 (37.8)
IIA 8 (4.1) 2 (5.3) 2 (4.4)
IIB 51 (26.0) 3 (7.9) 6 (13.3)
IIIA 14 (7.1) 1 (2.6) 2 (4.4)
IIIB 16 (8.2) 3 (7.9) 4 (8.9)
T-status 0.194
T1 55 (28.1) 18 (47.4) 16 (35.6)
T2 107 (54.6) 16 (42.1) 24 (53.3)
T3 18 (9.2) 1 (2.6) 1 (2.2)
T4 16 (8.2) 3 (7.9) 4 (8.9)
N-status 0.282
N0 132 (67.3) 32 (84.2) 34 (75.6)
N1 50 (25.5) 5 (13.2) 9 (20.0)
N2 14 (7.1) 1 (2.6) 2 (4.4)
Type of operation 0.081
(Bi)lobectomy 129 (65.8) 32 (84.2) 31 (68.9)
Pneumonectomy 67 (34.2) 6 (15.8) 14 (31.1)
Size of the tumor
a (cm) 4.00 (1–16) 2.95 (1–13) 3.10 (1–14) 0.049
Radiotherapy 0.385
No 157 (80.1) 34 (89.5) 36 (80.0)
Received 39 (19.9) 4 (10.5) 9 (20.0)
aFor continuous variables, figures are median (range).
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microvessel density (aMVD) have been shown to be at the
invading front of the tumours in NSCLC (Giatromanolaki et al,
2000; Koukourakis et al, 2000). Furthermore, the expression of
other angiogenic factors, such as Angiopoietin I and Angiopoietin
II have been principally observed at the edge of the tumour in
NSCLC (Tanaka et al, 2002).
Our method differs from that of Pezzella et al by the use of H&E
sections only for the classification into growth patterns without
additional sections stained immunohistochemically with vascular
markers. Our use of H&E sections has the advantage of allowing
the classification into growth patterns to be carried out in routine
daily pathological practice. It is possible that minimal angiogenesis
might occur in broadened co-opted alveolar walls: in the minority
of cases where this is a possibility, angiogenesis could be assessed
using vascular immunostaining.
Our proposed system not only contains elements of a
classification according to angiogenic profile but in addition also
emphasises differences in the formation and destruction of stroma
(Figure 1).
Noguchi et al (1995) proposed a new histological classification
for small adenocarcinomas of the lung measuring 2cm or less in
greatest diameter. In this classification, the type A and B – that is,
localised BAC without and with foci of collapse of alveolar
structures – were associated with an excellent prognosis (100%
5-year survival). The type A and B are considered to be in situ
peripheral adenocarcinomas. The growth pattern classification
described in the present paper does not apply to in situ peripheral
lung adenocarcinomas.
Other groups have studied the prognostic value of the alveolar
growth pattern: Offersen et al (2001) studied 143 patients with
different stages of NSCLC. The tumours were divided into two
groups; alveolar (entirely or partially) and angiogenic. In a Cox
multiple regression analysis for overall survival, advanced stage,
higher age, adenocarcinoma and angiogenic vascular pattern were
independent predictors of poor prognosis, while a better prognosis
was found for the alveolar growth pattern. No representative tissue
was available to examine the interface of the tumours in 46 patients
(32%). The paraffin block containing the tumour tissue was chosen
blindly in each patient, so no analysis of other sections was
performed. Moreover, the median time to death for 112 patients
was 22 months (range: 0–110), suggesting that operative mortality
was not excluded. Finally, the papillary growth pattern (which was
found by us to have an equally poor prognosis as the alveolar
growth pattern and was exclusively present in adenocarcinoma)
was classified by them in the angiogenic group. Our finding that
the papillary growth pattern has a poor prognosis, similar to that
of alveolar growth pattern, is a novel finding and has not been
shown before.
In a recent study by Funai et al (2003), 204 surgically resected
squamous cell lung carcinomas were analysed. A subset of 109
peripheral carcinomas were classified into three subtypes: (1) five
cases of the alveolar space-filling type, (2) 54 cases of the
expanding type and (3) 50 cases of the combined type. None of
the five cases of the alveolar space-filling type showed any
lymphatic vessel invasion, lymph node metastasis or pulmonary
metastasis. The Kaplan–Meier survival estimate at 5 years for the
alveolar space-filling type was 100%, as no event (death was the
endpoint) was recorded for these patients. The authors concluded
that a tumour of the alveolar space-filling type had the most
favourable prognosis, might be an incipient carcinoma corre-
sponding to squamous cell carcinoma in situ, and limited resection
could be acceptable in this tumour type. These conclusions must
be interpreted cautiously as the analyses were performed in a small
subset of patients and results were based on univariate analysis of
five patients.
The conclusion that patients with an alveolar, nonangiogenic
growth pattern have a worse prognosis seems to be paradoxical in
view of numerous studies describing an association between high
MVD and poor prognosis. The rationale of counting microvessels
Table 5 Cox multiple regression for overall survival
Factor Hazard ratio 95% CI
a P-value
Growth pattern 0.007
Destructive 1
Papillary 1.977 1.169–3.345 0.011
Alveolar 1.825 1.117–2.980 0.016
N-status 0.001
N0 1
N1 1.969 1.244–3.118 0.035
N2 2.961 1.526–5.748 0.009
Age 1.029 1.005–1.054 0.020
Type of operation
(bi)lobectomy 1
Pneumonectomy 1.530 0.989–2.369 0.056
a95% CI¼95% confidence interval.
Table 6 Cox multiple regression for disease-free survival
Factor Hazard ratio 95% CI
a P-value
Growth pattern 0.007
Destructive 1
Papillary 1.665 0.966–2.871 0.067
Alveolar 2.023 1.264–3.235 0.003
N-status o0.001
N0 1
N1 1.795 1.277–3.062 0.002
N2 2.717 1.930–5.060 o0.001
Type of operation
Lobectomy 1
Pneumonectomy 1.478 0.946–2.309 0.089
a95% CI¼95% confidence interval.
Table 7 Cox multiple regression for overall survival for patients in stage I
Factor Hazard ratio 95% CI
a P-value
Growth pattern 0.023
Destructive 1
Papillary 2.262 1.183–4.325 0.014
Alveolar 1.937 0.980–3.825 0.057
Age 1.050 1.012–1090 0.010
a95% CI¼95% confidence interval.
Table 8 Cox multiple regression for disease-free survival for patients in
stage I
Factor Hazard ratio 95% CI
a P-value
Growth pattern 0.056
Destructive 1
Papillary 1.959 0.988–3.882 0.054
Alveolar 1.989 1.004–3.942 0.049
a95% CI¼95% confidence interval.
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cell clones with the highest angiogenic potential and, consequently,
with easiest access to the blood stream and with an increased
probability of producing metastases capable of becoming angio-
genic and growing tumours (Vermeulen et al, 2002a). However,
angiogenesis induces a chaotic and inefficient vascularisation. The
vascularisation of the nonangiogenic growth pattern is more
efficient, implying a better growth and progression for nonangio-
genic tumour tissue. The prognostic value of MVD has been a
controversial subject in NSCLC (Giatromanolaki et al, 1996;
Chandrachud et al, 1997; Fontanini et al, 1997; Pastorino et al,
1997; Duarte et al, 1998; Matsuyama et al, 1998; Ohta et al, 1999;
O’Byrne et al, 2000; Offersen et al, 2001; Tsoli et al, 2002). The
largest study of 515 patients with the longest follow-up time found
no prognostic value for MVD (Pastorino et al, 1997). In our view,
this is because all studies contained tumours with different growth
patterns, different angiogenic profiles and different prognosis
(Sardari Nia et al, 2003). The prognostic value of MVD can only be
investigated in the subgroup with an angiogenic growth pattern.
Such a study has yet to be performed.
The clinical implications of our results are three-fold. Firstly,
tumours with a nonangiogenic growth pattern will probably not
respond to treatment with angiogenesis inhibitors. This resistance
to antiangiogenic therapy will probably occur irrespective of
whether a tumour is entirely or partially (only at the interface)
nonangiogenic: nonangiogenic clones might be selected by
antiangiogenic treatment. The growth pattern can be used as a
surrogate marker of angiogenesis, and pretreatment patient
selection based on the growth pattern could enlarge the fraction
of patients responding to angiogenesis inhibitors.
Secondly, the proposed classification has a strong independent
prognostic value for overall and disease-free survival. The growth
patterns are a possible explanation for differences in survival of
patients in the same stage. In stage I resected NSCLC, many
patients are long-term survivors, but some relapse early and die.
The patients with early relapse and reduced overall survival are
those with an alveolar and papillary growth pattern. These ‘at risk’
patients may be identified based on the growth pattern and can be
intensively followed or treated with adjuvant therapy.
Finally, in this study, we propose the hypothesis that the growth
pattern of a tumour is the synthesis of different biological
characteristics. The differences in clinical outcome and response
to a specific treatment modality of patients in the same stage of
disease are due to differences in biological characteristics of the
tumours. This implies that different growth patterns might
respond differently to specific treatment modalities, such as
chemotherapy, antiangiogenic therapy and radiotherapy. This
could provide new opportunities for the treatment of lung cancer
and warrants further study.
In conclusion, the growth patterns identified have prognostic
value additional to that provided by staging of the disease, and give
a possible explanation for survival differences at the same stage. A
prospective study would validate the results presented here and
demonstrate the clinical usefulness of growth pattern identification.
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